Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25660784 | 1.00 | CTNNB1 (0.45) | CTNNB1MTNR1ASIGMAR1CYP1A2CYP2C19 | |
| SCHEMBL9631575 | 1.00 | CTNNB1 (0.45) | CTNNB1MTNR1ASIGMAR1CYP1A2CYP2C19 | |
| SCHEMBL2269291 | 0.82 | TACR1 (0.51) | CTNNB1MMP9CASP1TDP1KMT2A | |
| SCHEMBL2270111 | 0.82 | TACR1 (0.51) | CTNNB1MMP9CASP1TDP1KMT2A | |
| SCHEMBL2544632 | 0.80 | CTNNB1 (0.52) | CTNNB1MMP9CASP1TDP1KMT2A | |
| SCHEMBL11399752 | 0.79 | SIGMAR1 (0.39) | CTNNB1MTNR1ASIGMAR1CYP1A2CYP2C19 | |
| SCHEMBL9852737 | 0.79 | CASP1 (0.48) | CTNNB1MTNR1AMMP9CASP1TDP1 | |
| SCHEMBL10857577 | 0.78 | CTNNB1 (0.49) | CTNNB1SIGMAR1CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL11275502 | 0.78 | CTNNB1 (0.51) | CTNNB1SIGMAR1CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL8484930 | 0.78 | CTNNB1 (0.51) | CTNNB1SIGMAR1CYP1A2CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5140009-A | Stable against proteolytic enzymes; anticarcinogenic agents; urogenital disorders | TAP PHARMACEUTICALS, INC. (US) | 1992-08-18 | — | — | US | claimed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | CTNNB1 2924/4885MTNR1A 2827/4885SIGMAR1 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.